

Financial Statements

June 30, 2023 and 2022

Table of Contents June 30, 2023 and 2022

| | Page |
|--|------|
| Independent Auditors' Report | 1 |
| Financial Statements | |
| Statements of Financial Position | 3 |
| Statements of Activities and Changes in Net Assets | 4 |
| Statements of Cash Flows | 5 |
| Notes to Financial Statements | 6 |



Independent Auditors' Report

To the Board of Trustees of Children's Hospital of Pittsburgh Foundation d/b/a UPMC Children's Hospital Foundation

Opinion

We have audited the financial statements of Children's Hospital of Pittsburgh Foundation d/b/a UPMC Children's Hospital Foundation (the Foundation), which comprise the statements of financial position as of June 30, 2023 and 2022, and the related statements of activities and changes in net assets and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Foundation as of June 30, 2023 and 2022, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America (GAAP).

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with GAAP, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the financial
 statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings and certain internal control-related matters that we identified during the audit.

Baker Tilly US, LLP

Pittsburgh, Pennsylvania October 25, 2023

Statements of Financial Position June 30, 2023 and 2022 (Amounts in Thousands)

| | 2023 | | 2022 | | : | 2023 | 2022 |
|---|------------|----------|---------|--|----|---------|---------------|
| Assets | | | | Liabilities and Net Assets | | | |
| Current Assets | | | | Current Liabilities | | | |
| Cash and cash equivalents | \$ 5,404 | \$ | 6,452 | Due to UPMC Children's Hospital of Pittsburgh: | | | |
| Current portion of pledges receivable | 11,620 | | 7,954 | Operating expenses | \$ | 1,143 | \$ 984 |
| Current portion of assets whose use is limited | 18,990 | | 18,542 | Annual financial support | | 4,284 | 2,333 |
| Current portion of investments, donor restricted | 6,152 | <u> </u> | 5,891 | Accrued expenses | | 93 | 6 |
| Total current assets | 42,166 | | 38,839 | Total liabilities | | 5,520 | 3,323 |
| Assets Whose Use is Limited, Board Designated | 151,117 | | 140,193 | Net Assets Without donor restrictions | | 154,534 | 142,954 |
| Investments, Donor Restricted | 162,496 | | 141,968 | With donor restrictions | | 226,249 | 197,188 |
| Pledges Receivable, Net | 18,700 | | 11,212 | Total net assets | | 380,783 | 340,142 |
| Beneficial Interest in Charitable Remainder Trusts | 339 | I | 315 | | | | |
| Beneficial Interest in Perpetual Trusts | 11,48 | <u> </u> | 10,938 | | | | |
| Total assets | \$ 386,303 | \$ | 343,465 | Total liabilities and net assets | \$ | 386,303 | \$ 343,465 |

Children's Hospital of Pittsburgh Foundation d/b/a UPMC Children's Hospital Foundation Statements of Activities and Changes in Net Assets Years Ended June 30, 2023 and 2022 (Amounts in Thousands)

| | 2023 Without Donor With Donor Restrictions Restrictions Total | | 2022 Without Donor With Donor Restrictions Restrictions | | Total | | | | | | | |
|--|---|---------|---|----------|-------|---------|----|----------|----|----------|----|-----------|
| Revenues and Other Sunnert | | | | | | | | | | | | |
| Revenues and Other Support Contributions and bequests | \$ | 14.603 | \$ | 36,909 | \$ | 51,512 | \$ | 9.776 | \$ | 33,892 | \$ | 43,668 |
| Interest and dividends, net of fees | Ŧ | 3,945 | Ŧ | 3,199 | Ŷ | 7,144 | Ŧ | 3,405 | Ŧ | 2,646 | Ŧ | 6,051 |
| Contributed services | | 484 | | - | | 484 | | 474 | | - | | 474 |
| Allowance for doubtful pledges and pledges written off | | - | | (564) | | (564) | | - | | (2) | | (2) |
| Total revenues and other support before | | | | | | | | | | | | |
| net assets released from restrictions | | 19,032 | | 39,544 | | 58,576 | | 13,655 | | 36,536 | | 50,191 |
| Net assets released from restrictions used for, | | | | | | | | | | | | |
| Annual financial support and other operating expenses | | 23,150 | | (23,150) | | - | | 21,527 | | (21,527) | | - |
| Total revenues and other support | | 42,182 | | 16,394 | | 58,576 | | 35,182 | | 15,009 | | 50,191 |
| Expenses | | | | | | | | | | | | |
| Contributions to UPMC Children's Hospital of Pittsburgh, | | | | | | | | | | | | |
| Annual financial support and petition requests | | 31,942 | | - | | 31,942 | | 33,204 | | - | | 33,204 |
| Fundraising | | 6,770 | | - | | 6,770 | | 5,646 | | - | | 5,646 |
| General and administrative | | 3,027 | | - | | 3,027 | | 3,993 | | - | | 3,993 |
| Total expenses | | 41,739 | | - | | 41,739 | | 42,843 | | - | | 42,843 |
| Increase (decrease) in net assets before other | | | | | | | | | | | | |
| changes in net assets | | 443 | | 16,394 | | 16,837 | | (7,661) | | 15,009 | | 7,348 |
| Other Changes in Net Assets | | | | | | | | | | | | |
| Net realized and unrealized gain (loss) on investments | | 12,254 | | 11,942 | | 24,196 | | (25,893) | | (22,685) | | (48,578) |
| Valuation gain (loss), beneficial interest in charitable remainder trusts | | _ | | 24 | | 24 | | _ | | (37) | | (37) |
| Valuation gain (loss), beneficial interest in perpetual trusts | | - | | 547 | | 547 | | | | (2,612) | | (2,612) |
| Reclassification of net assets | | (1,117) | | 1,117 | | - | | (94) | | 94 | | (_,0 : _) |
| Transfer of net assets | | - | | (963) | | (963) | | - | | (315) | | (315) |
| Increase (decrease) in net assets | | 11,580 | | 29,061 | | 40,641 | | (33,648) | | (10,546) | | (44,194) |
| Net Assets, Beginning | | 142,954 | | 197,188 | | 340,142 | | 176,602 | | 207,734 | | 384,336 |
| Net Assets, Ending | \$ | 154,534 | \$ | 226,249 | \$ | 380,783 | \$ | 142,954 | \$ | 197,188 | \$ | 340,142 |

See notes to financial statements

Statements of Cash Flows Years Ended June 30, 2023 and 2022 (Amounts in Thousands)

| | | 2023 | 2022 | | |
|--|----------|----------|----------|----------------|--|
| Cash Flows From Operating Activities | | | | | |
| Increase (decrease) in net assets | \$ | 40,641 | \$ | (44,194) | |
| Adjustments to reconcile increase (decrease) in net assets to net | Ŧ | , | Ŧ | (, , | |
| cash provided by (used in) operating activities: | | | | | |
| Provision for doubtful pledges | | 309 | | 2 | |
| Net realized and unrealized (gains) losses on investments | | (24,196) | | 48,578 | |
| Valuation (gain) loss, beneficial interest in charitable | | | | | |
| remainder trusts | | (24) | | 37 | |
| Valuation (gain) loss, beneficial interest in perpetual trusts | | (547) | | 2,612 | |
| Contributions of endowment funds restricted in perpetuity | | (3,564) | | (4,192) | |
| Changes in assets and liabilities: | | (11 462) | | (10, 707) | |
| Pledges receivable Due to UPMC Children's Hospital of Pittsburgh: | | (11,463) | | (10,787) | |
| Operating expenses | | 159 | | 162 | |
| Annual financial support | | 1,951 | | 77 | |
| Accrued expenses | | 87 | | (2) | |
| | | 0. | | (-/ | |
| Net cash provided by (used in) operating activities | | 3,353 | | (7,707) | |
| Cash Flows (Used in) Provided by Investing Activities | | | | | |
| Net (purchases) sales and maturities of investments and | | | | | |
| assets whose use is limited | | (3,875) | | 3,791 | |
| Cook Elowe Drovided by Eineneing Activities | | | | | |
| Cash Flows Provided by Financing Activities Contributions of endowment funds restricted in perpetuity | | 3,564 | | 4,192 | |
| Contributions of endowment funds restricted in perpetativ | | 3,304 | | 4,192 | |
| Net increase in cash and cash equivalents and restricted | | | | | |
| cash and cash equivalents | | 3,042 | | 276 | |
| | | | | | |
| Cash and Cash Equivalents and Restricted Cash and Cash | | 11 100 | | 44 400 | |
| Equivalents, Beginning | | 11,469 | | 11,193 | |
| Cash and Cash Equivalents and Restricted Cash and Cash | | | | | |
| Equivalents, Ending | \$ | 14,511 | \$ | 11,469 | |
| | | | | | |
| Reconciliation of Cash and Cash Equivalents and Restricted Cash | | | | | |
| and Cash Equivalents to Statements of Financial Position | ~ | E 404 | ^ | 0.450 | |
| Cash and cash equivalents | \$ | 5,404 | \$ | 6,452 5,017 | |
| Cash and cash equivalents included in assets whose use is limited | | 9,107 | | 5,017 | |
| Total cash and cash equivalents and | | | | | |
| restricted cash and cash equivalents | \$ | 14,511 | \$ | 11,469 | |
| · | | | | | |

1. Organization

Children's Hospital of Pittsburgh Foundation d/b/a UPMC Children's Hospital Foundation (the Foundation) was created on July 1, 2000, primarily to support the fund-raising and development efforts of the Children's Hospital of Pittsburgh.

2. Affiliation Agreement

On October 31, 2001, Children's Hospital of Pittsburgh consummated an affiliation with University of Pittsburgh Medical Center (UPMC Health System or UPMC) pursuant to the terms of the Integration and Affiliation Agreement (the Affiliation Agreement) by and among the Children's Hospital of Pittsburgh, the Foundation, and UPMC Health System (collectively, the Parties). As a result of the Affiliation Agreement, Children's Hospital of Pittsburgh became UPMC Children's Hospital of Pittsburgh (the Hospital). Under the terms of the Affiliation Agreement, the Foundation was reorganized such that the UPMC Children's Hospital of Pittsburgh was no longer the sole corporate member of the Foundation and the Foundation has no corporate member. The Foundation is structured as a supporting organization of the Hospital.

The terms of the Affiliation Agreement provided that UPMC Health System would construct a new pediatric hospital (the New CHP) for the Hospital. Pursuant to an amendment entered into by the Parties on September 28, 2004, the Foundation was required to provide funding for the New CHP in the amount of \$50,000 (the Initial Funding Commitment). The Initial Funding Commitment was fulfilled upon completion of the New CHP in May 2009.

In January 2007, the Affiliation Oversight Committee approved an increase to the projected cost for the design and construction of the New CHP of \$46,800 and the Foundation agreed in September 2007 to fund the \$46,800 increased project costs (Additional Funding Commitment). The Additional Funding Commitment was fulfilled in October 2013.

The Affiliation Agreement required the Hospital, after receiving Orphan's Court and regulatory approval, to transfer to the Foundation certain unrestricted and restricted investments, as well as the Hospital's beneficial interests in certain perpetual trusts. The Affiliation Agreement requires that the Foundation, for the longer of 20 years or for so long as the Foundation supports the mission of the Hospital, will provide annual financial support equal to 5% of the rolling average corpus of such transferred investments, beneficial interests in certain perpetual trusts and donations received thereafter, unless the original donor specified a different spending provision. This annual funding commitment is conditional upon the Hospital delivering to the Foundation a broad range of funding requests, and to meet certain standards selected by the Parties as indicators of the Hospital's continued or improved performance.

3. Summary of Significant Accounting Policies

Basis of Presentation

The financial statements of the Foundation have been prepared in conformity with accounting principles generally accepted in the United States of America, including accounting standards as they relate to financial statements of not-for-profit organizations. The Financial Accounting Standards Board's (FASB) guidance requires the reporting of total assets, liabilities and net assets in a statement of financial position; reporting the change in net assets in a statement of activities; reporting the sources and uses of cash and cash equivalents in a statement of cash flows, and reporting expenses by natural and functional classification.

Net assets and revenues, gains, expenses and losses are classified as without donor restriction or with donor restriction based on the existence or absence of donor-imposed restrictions as follows:

Net Assets Without Donor Restrictions - Net assets that are not subject to donor-imposed stipulations. Net assets without donor restrictions may be designated for specific purposes by action of the Board of Trustees (the Board) or may otherwise be limited by contractual agreements with outside parties.

Net Assets With Donor Restrictions - Net assets whose use by the Foundation is subject to donor-imposed stipulations that can be fulfilled by actions of the Foundation pursuant to those stipulations or that expire by the passage of time are reported as net assets with donor restrictions. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, these net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities and changes in net assets as net assets released from donor restrictions. Additionally, funds received as gifts and bequests which have been accepted with the donor stipulation that the principal be maintained intact in perpetuity are reported as net assets with donor restrictions.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Subsequent Events

The Foundation evaluated subsequent events for recognition or disclosure through October 25, 2023, the date the financial statements were available to be issued.

Cash and Cash Equivalents

Cash and cash equivalents include highly liquid investments with an original maturity of three months or less at the date of purchase, excluding assets whose use is limited and investments.

No collateral or security is provided on these investments, other than the insurance on interest bearing deposits per financial institution by the Federal Deposit Insurance Corporation. The Foundation has not experienced any losses from maintaining these accounts in excess of federally insured limits. Management believes it is not subject to significant risks associated with these accounts.

Pledges Receivable

Unconditional pledges to contribute cash and other assets are reported at their estimated fair value at the date the promise is received. Pledges receivable that are expected to be collected within one year are recorded at their net realizable value. Pledges receivable that are expected to be collected in future years are recorded at the present value of estimated net realizable future cash flows. The discount rate used was 4.49% at June 30, 2023 and 2.99% at June 30, 2022.

The Foundation annually evaluates the collectability of its pledges receivable and either reserves for or writes off uncollectible pledges when it is determined the pledge is uncollectible.

Conditional promises to give, that is, those with a measurable performance or other barrier, and a right of return, are not included as support until such time as the conditions are substantially met.

Investments and Assets Whose Use Is Limited

The Foundation's investments are reported in the statements of financial position as follows:

Assets Whose Use is Limited, Board Designated - These investments represent funds where the Board has restricted the use over the corpus, and funds of which the Board retains control and may at its discretion subsequently use for other purposes.

Investments, Donor Restricted - These investments represent primarily endowed funds for which the corpus is restricted and the related investment income is restricted for specifically designated expenditures.

Investments are in equity investments, fixed income investments and alternative investment strategies, including hedge funds and private equity.

Investments with readily determinable fair values and all investments in debt securities are measured at fair value in the statements of financial position. Investment income or loss (including realized and unrealized gains and losses on investments, interest and dividends, net of investment fees) is included in the determination of increase (decrease) in net assets without donor restrictions unless the income is restricted by donor or law. Interest income is recorded as earned on the accrual basis using the effective yield method. Dividends are recorded on the accrual basis based on the ex-dividend date.

The fair value of the Foundation's alternative investments is based on the beginning value of the Foundation's interest in the investment plus actual contributions and allocated investment income or loss less actual distributions and allocated administrative expense. If available, quoted market prices are used to value alternative investments. Securities that have no available quoted market price are presented at estimated fair value as determined by the trustee using the net asset value practical expedient.

Although the Foundation's investments are invested in a variety of financial instruments, the related fair values, as reported in the statements of financial position, are subject to various market risks, including changes in the equity markets, the interest rate environment and economic conditions. Due to the level of risk associated with investment securities and the level of uncertainty related to changes in the fair value of investment securities, it is reasonably possible that the fair value of investments reported in the accompanying statements of financial position could materially change in the near future.

Beneficial Interest in Charitable Remainder Trusts

The Foundation has been designated as the beneficiary of certain charitable remainder trusts created by donors and held by entities other than the Foundation. Under the terms of the trusts, the Foundation will receive a portion of the assets that remain in the trusts when they are terminated, typically upon death of the current beneficiary. Upon being designated as the beneficiary, the Foundation recorded an asset and recognized contribution revenues with donor restrictions. The beneficial interest recorded by the Foundation is measured at the present value of the estimated future cash payments to be distributed to the Foundation. Subsequent changes in fair value are recorded as valuation gains or losses in net assets with donor restrictions.

Notes to Financial Statements June 30, 2023 and 2022 (Amounts in Thousands)

Beneficial Interest in Perpetual Trusts

The Foundation has been designated as the beneficiary of certain perpetual trusts created by donors and held by entities other than the Foundation. Under the terms of the trusts, the Foundation will receive a portion of the income earned on trust assets in perpetuity. Upon being designated as the beneficiary, the Foundation recorded an asset and recognized contribution revenues with donor restrictions. The beneficial interest recorded by the Foundation is measured at the fair value of the Foundation's interest in the trust assets. Subsequent changes in fair value are recorded as valuation gains or losses in net assets with donor restrictions.

Donor Restricted Gifts

The Affiliation Agreement provides that all contributions from donors received for the benefit of the Hospital will be recorded and maintained by the Foundation. Contributions are considered to be available for use unless specifically restricted by the donor. Amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as support with donor restrictions.

Income Tax Status

The Foundation is a not-for-profit organization as described in Section 501(c)(3) of the Internal Revenue Code (IRC), and is exempt from federal taxes on its exempt income under Section 501(a) of the IRC. Accordingly, no provision for federal and state income taxes is recorded.

The Foundation accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the tax uncertainty occurs if the recognition threshold is met. Management determined there were no tax uncertainties that met the recognition threshold at June 30, 2023 and 2022.

4. Pledges Receivable

Pledges receivable consist of the following at June 30:

| | 2023 | | | 2022 | | |
|--|------|---------------------------|----|-------------------------|--|--|
| Pledges due within one year Pledges due in one to five years Pledges due in more than five years | \$ | 11,620 14,158 6,349 | \$ | 7,954 7,403 5,409 | | |
| Total pledges receivable, gross | | 32,127 | | 20,766 | | |
| Less discount to net present value | | 1,807 | | 1,600 | | |
| Total pledges receivable, net | | 30,320 | | 19,166 | | |
| Less current portion of pledges receivable | | 11,620 | | 7,954 | | |
| Noncurrent portion of pledges receivable | \$ | 18,700 | \$ | 11,212 | | |

5. Investments and Assets Whose Use is Limited

Investments and assets whose use is limited consist of the following at June 30:

| | 2023 | 2022 | |
|---|---------------|---------------|--|
| Cash and cash equivalents | \$ 9,107 | \$ 5,017 | |
| U.S. government obligations | 31,571 | 20,329 | |
| Corporate bonds | 16,484 | 17,808 | |
| Mortgage and asset backed obligations | 10,102 | 9,962 | |
| Mutual funds: | | | |
| International | 97,453 | 91,141 | |
| Large-cap | 102,991 | 90,430 | |
| Mid-cap | 28,660 | 26,085 | |
| Small-cap | 18,706 | 16,321 | |
| Alternative investments: | | | |
| Private investment partnership funds | 17,069 | 23,361 | |
| Distressed debt funds | 6,612 | 6,140 | |
| Total investments and assets whose use is limited | \$ 338,755 | \$ 306,594 | |

Investments and assets whose use is limited are reported in the accompanying statements of financial position as follows:

| | 2023 | 2022 | | |
|---|---------------|------|---------|--|
| Current portion of assets whose use is limited | \$ 18,990 | \$ | 18,542 | |
| Current portion of investments, donor restricted | 6,152 | | 5,891 | |
| Assets whose use is limited, board designated | 151,117 | | 140,193 | |
| Investments, donor restricted | 162,496 | | 141,968 | |
| Total investments and assets whose use is limited | \$ 338,755 | \$ | 306,594 | |

The current portions of assets whose use is limited and investments are based upon management's estimate of the amounts required to meet the Foundation's annual financial support to the Hospital in the following year.

The Foundation's investments, primarily held with PNC Bank, consist of cash and cash equivalents, mutual funds, corporate bonds, government obligations and certain alternative investments. The fair value of the Foundation's alternative investments have been valued using the net asset value practical expedient in the absence of readily determinable fair values. Management's estimates are based on information provided by the fund managers or the general partners of these investments.

The Foundation's private investment partnership funds and distressed debt fund agreements obligate the Foundation to provide advance funding periodically up to specified levels. The Foundation had unfunded commitments of \$2,577 at June 30, 2023 and \$3,361 at June 30, 2022 to a variety of private equity, natural resources, venture capital and international funds. The Foundation expects these commitments to be funded over the next several years, depending on market conditions.

The Foundation's private investment partnership funds and distressed debt funds cannot be redeemed. Instead, the nature of these investments is that distributions are received through the liquidation of the underlying assets of the funds. The Foundation does have the ability to sell these funds on secondary markets.

Total investment return, net of related investment fees, consists of the following:

| | 2023 | | 2022 |
|--|------|----------------|----------------------|
| Interest and dividends Less investment fees | \$ | 7,257 (113) | \$ 6,183 (132) |
| Interest and dividends, net | | 7,144 | 6,051 |
| Net realized and unrealized gains (losses) | | 24,196 | (48,578) |
| Total investment return | \$ | 31,340 | \$ (42,527) |

6. Fair Value Measurements

The Foundation measures its investments and assets whose use is limited, beneficial interest in charitable remainder trusts, and beneficial interest in perpetual trusts at fair value on a recurring basis in accordance with accounting principles generally accepted in the United States of America. Fair value is defined as the price that would be received to sell an asset or the price that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The framework that the authoritative guidance establishes for measuring fair value includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs used in determining valuations into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement.

The levels of the fair value hierarchy are as follows:

Level 1 - Fair value is based on unadjusted quoted prices in active markets that are accessible to the Foundation for identical assets. These generally provide the most reliable evidence and are used to measure fair value whenever available.

Level 2 - Fair value is based on significant inputs, other than Level 1 inputs, that are observable either directly or indirectly for substantially the full term of the asset through corroboration with observable market data. Level 2 inputs include quoted market prices in active markets for similar assets, quoted market prices in markets that are not active for identical or similar assets, and other observable inputs.

Level 3 - Fair value is based on significant unobservable inputs. Examples of valuation methodologies that would result in Level 3 classification include option pricing models, discounted cash flows, and other similar techniques.

Notes to Financial Statements June 30, 2023 and 2022 (Amounts in Thousands)

The following tables present the Foundation's financial instruments measured and reported at fair value at June 30, 2023 and 2022:

| | 2023 | | | | | | | |
|--|------|-------------------|----|----------|----|------------------|-----------------|-------------------|
| | | Level 1 | | Level 2 | | evel 3 | Total Fair Valu | |
| Investments and assets whose use is limited: | | | | | | | | |
| U.S. government obligations Corporate bonds | \$ | 31,571 16,484 | \$ | - | \$ | - | \$ | 31,571 16,484 |
| Mortgage and asset backed obligations Mutual funds | | 10,102 247,810 | | - | | - | | 10,102 247,810 |
| Total | | 305,967 | | | | - | | 305,967 |
| Investments and assets whose use is limited reported at net asset value: Private investment partnership funds Distressed debt funds | | | | | | | | 17,069 6,612 |
| Cash and cash equivalents | | | | | | | | 9,107 |
| Total investments and assets whose use is limited | | | | | | | | 338,755 |
| Beneficial interest in charitable remainder trusts Beneficial interest in perpetual | | - | | - | | 339 | | 339 |
| trusts Total | \$ | - 305,967 | \$ | <u> </u> | \$ | 11,485 11,824 | \$ | 11,485 350,579 |

Notes to Financial Statements June 30, 2023 and 2022 (Amounts in Thousands)

| | 2022 | | | | | | | | |
|--|------|------------------|----|---------|----|--------|------------------|------------------|--|
| | | Level 1 | | Level 2 | | evel 3 | Total Fair Value | | |
| Investments and assets whose use is limited: | | | | | | | | | |
| U.S. government obligations Corporate bonds | \$ | 20,329 17,808 | \$ | - | \$ | - | \$ | 20,329 17,808 | |
| Mortgage and asset backed obligations Mutual funds | | 9,962 223,977 | | - | | - | | 9,962 223,977 | |
| Total | | 272,076 | | - | | - | | 272,076 | |
| Investments and assets whose use is limited reported at net asset value: Private investment | | | | | | | | | |
| partnership funds Distressed debt funds | | | | | | | | 23,361 6,140 | |
| Cash and cash equivalents | | | | | | | | 5,017 | |
| Total investments and assets whose use is limited | | | | | | | | 306,594 | |
| Beneficial interest in charitable remainder trusts Beneficial interest in perpetual | | - | | - | | 315 | | 315 | |
| trusts | | - | | - | | 10,938 | | 10,938 | |
| Total | \$ | 272,076 | \$ | | \$ | 11,253 | \$ | 317,847 | |

Certain investments that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented in the statements of financial position.

The table below sets forth a summary of certain changes in the fair value of the Foundation's Level 3 assets for the years ended June 30:

| | | | 2 | 023 | | |
|---|-----------------------|---|-------------|--------------------------------------|----|----------|
| | Inter Char Rema | eficial est in itable ainder usts | Inte Per | eficial rest in petual usts | T | otal |
| Purchases/additions Sales/deductions | \$ | 24 - | \$ | 547 - | \$ | 571 - |

Notes to Financial Statements June 30, 2023 and 2022 (Amounts in Thousands)

| | | | | 2022 | | | |
|---|-----------------------|--|----|--------------|-------|--------------|--|
| | Inter Char Rema | Beneficial Interest in Charitable Remainder Trusts | | | Total | | |
| Purchases/additions Sales/deductions | \$ | - (37) | \$ | - (2,612) | \$ | - (2,649) | |

The following is a description of the valuation methodologies used for financial instruments reported at fair value. There have been no changes in methodologies used at June 30, 2023 and 2022.

Corporate bonds, U.S. government obligations, and mortgage and asset backed obligations are valued at fair value based on quoted market prices for identical securities in active markets that the Foundation has the ability to access at the measurement date.

Mutual funds are valued at fair value, based on quoted market prices for identical securities in active markets that the Foundation has the ability to access at the measurement date.

The Foundation's private investment partnership funds and distressed debt funds have been valued using the net asset value practical expedient in the absence of readily determinable fair values. Management's estimates are based on information provided by the fund managers or the general partners of these investments.

The private investment partnership funds' investment objective is to seek the preservation of capital and to provide long-term rates of return in excess of the publicly traded markets. The Foundation is invested in eight separate funds invested in a variety of markets, including venture capital, domestic private equity, international private equity and natural resources.

The distressed debt funds' investment objective is to seek the preservation of capital and to provide long-term rates of return comparable to returns generated by top performing domestic fixed income funds. The Foundation is invested in five separate funds invested in a variety of corporate equity and debt instruments.

The beneficial interest in charitable remainder trusts is valued at fair value based on the net present value of the future distributions of the trust assets.

The beneficial interest in perpetual trusts is valued at fair value based on the Foundation's interest in the fair value of the assets held by the trust, which represents a proxy for the discounted present value of future cash flows.

The preceding methods may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Foundation believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

7. Liquidity and Availability of Resources

The following table reflects the Foundation's financial assets available for general expenditure within one year at June 30, 2023 and 2022. Financial assets are considered unavailable when illiquid or not convertible to cash within one year. Unavailable financial assets consist of donor restricted funds not expected to be released from restrictions within the next year, and investments with redemption restrictions.

| | | 2023 | 2022 | |
|--|----|---|------|--|
| Financial assets: Cash and cash equivalents Current portion of pledges receivable Current portion of assets whose use is limited Current portion of investments Assets whose use is limited, board designated | | 5,404 11,620 18,990 6,152 151,117 | \$ | 6,452 7,954 18,542 5,891 140,193 |
| Total financial assets | | 193,283 | | 179,032 |
| Less financial assets unavailable for general expenditures within one year: Current portion of pledges receivable whose proceeds are donor restricted Investments with redemption restrictions | | (9,532) (23,681) | | (7,369) (29,501) |
| Total financial assets available to meet cash needs for general expenditures within one year | \$ | 160,070 | \$ | 142,162 |

As part of the Foundation's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities and other obligations come due. The Foundation invests cash in excess of daily requirements at the discretion of the Board.

8. Net Assets With Donor Restrictions

Net assets with donor restrictions consist of the following at June 30:

| | 2023 | | 2022 | |
|--|-------------------------------|---------|---------------------------|--|
| Restricted for specific purposes: Research Healthcare services and programs | \$ 26,001 118,449 | \$ | 22,769 97,070 | |
| Total restricted for specific purposes | 144,450 | 119,839 | | |
| Restricted in perpetuity: Endowment funds Beneficial interest in perpetual trusts Pledges receivable, proceeds to be permanently restricted | 65,092 11,485 5,222 | | 61,521 10,938 4,890 | |
| Total restricted in perpetuity | 81,799 | | 77,349 | |
| Total net assets with donor restrictions | \$ 226,249 | \$ | 197,188 | |

The income earned from endowment funds is primarily restricted to support research activities. The income generated from beneficial interests in perpetual trusts is available for operations unless restricted as established by each trust agreement. The restricted purposes as established by certain trusts includes benevolent care and special purpose funds.

9. Endowment Funds

The Foundation's endowments were established for a variety of purposes, and include both donor-restricted endowment funds and funds designated by the Board to function as endowments. As required by FASB authoritative guidance, net assets associated with endowment funds, including funds designated by the Board to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

Interpretation of Relevant Law

The Foundation interprets the Commonwealth of Pennsylvania Act 141 (PA Act 141) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. Further it is also the Foundation's interpretation that the PA Act 141 allows for the use of 5% of the fair value of the gift to the extent that the investment return was not sufficient to fund the purpose of the gift during the year. As a result of this interpretation, the Foundation classifies as net assets with donor restrictions to be held in perpetuity: (a) the original value of gifts donated to the endowment; and (b) the original value of subsequent gifts to the endowment. The remaining portion of the donor-restricted endowment fund is classified as net assets with donor restrictions until those amounts are appropriated for expenditure by the Foundation in a manner consistent with the standard of prudence prescribed by PA Act 141.

Endowment Fund Activity

The Foundation's endowment funds consist of the following at June 30:

| | 2023 | 2022 | | |
|--|---------------------------------|------|---------------------------|--|
| Board designated Available for expenditures for specific purposes Original corpus restricted in perpetuity | \$ 2,496 61,032 65,092 | \$ | 2,273 54,022 61,521 | |
| Total endowment funds | \$ 128,620 | \$ | 117,816 | |

The changes in endowment net assets is comprised of the following for the years ended June 30, 2023 and 2022:

| | 2023 | | | | | | | |
|---|------|------------------|----|-------------------------|-----------------------------|------------|-------|-----------------|
| | | Board ignated | | ilable for enditures | Restricted in Perpetuity | | Total | |
| Endowment net assets, beginning of year | \$ | 2,273 | \$ | 54,022 | \$ | 61,521 | \$ | 117,816 |
| Investment return Contributions Reclassifications and other | | 223 | | 15,138 - | | - 3,564 | | 15,361 3,564 |
| changes Appropriation of endowment assets for expenditures, | | - | | - | | 7 | | 7 |
| annual transfer for operations | | - | | (8,128) | | - | | (8,128) |
| Endowment net assets, end of year | \$ | 2,496 | \$ | 61,032 | \$ | 65,092 | \$ | 128,620 |

Notes to Financial Statements June 30, 2023 and 2022 (Amounts in Thousands)

| | 2022 | | | | | | | |
|---|------|----------------|-------------------------------|---------------|-----------------------------|------------|----|-------------------|
| | _ | oard gnated | Available for Expenditures | | Restricted in Perpetuity | | | Total |
| Endowment net assets, beginning of year | \$ | 2,551 | \$ | 75,508 | \$ | 57,343 | \$ | 135,402 |
| Investment return Contributions Reclassifications and other | | (278) - | | (19,129) - | | - 4,192 | | (19,407) 4,192 |
| changes Appropriation of endowment assets for expenditures, | | - | | - | | (14) | | (14) |
| annual transfer for operations | | | | (2,357) | | | | (2,357) |
| Endowment net assets, end of year | \$ | 2,273 | \$ | 54,022 | \$ | 61,521 | \$ | 117,816 |

Funds With Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor or PA Act 141 requires the Foundation to retain as a fund of perpetual duration. In accordance with FASB authoritative guidance deficiencies of this nature that are reported in net assets with donor restrictions were \$15 and \$318 at June 30, 2023 and 2022, respectively.

Return Objectives and Risk Parameters

The investment philosophy of the Foundation is based on a disciplined, consistent and diversified approach utilizing multiple asset classes and multiple managers. The Foundation's intent is to accommodate styles and strategies considered reasonable and prudent. Assets are invested with investment managers who invest in mutual funds, corporate bonds and governmental obligations. Additionally, a portion of the funds are invested in alternative investments which include investments in private investment partnership funds and distressed debt funds. The primary objective is to grow the assets to ensure the Foundation can continue to support the Hospital's operations.

Strategies Employed for Achieving Objectives

To satisfy its long-term rate of return objectives, the Foundation relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Foundation targets a diversified asset allocation that is set by the Foundation's Finance and Investment Committee. The investment assets are invested according to the following asset allocation guideline:

| | Current Targets | Long-Term Future Target Range |
|----------------------------------|--------------------|-------------------------------------|
| Domestic large-cap equity | 30.00 % | 15.00 - 35.00 % |
| Domestic mid to small-cap equity | 15.00 | 5.00 - 17.50 |
| International developed equity | 15.00 | 8.00 - 18.50 |
| Emerging markets | 15.00 | 8.00 - 18.50 |
| Fixed income | 20.00 | 8.00 - 30.00 |
| Hedge funds | 0.00 | 0.00 - 10.00 |
| Private equity | 5.00 | 0.00 - 15.00 |

Spending Policy and How the Investment Objectives Relate to Spending Policy

PA Act 141 states that provided an organization adopts and follows an investment policy seeking a total return for the assets held, the organization may annually select a spending percentage between 2% and 7% of the three year average fair market value of the assets held by an organization.

The Affiliation Agreement requires that the Foundation will provide annual financial support equal to 5% of the rolling 12 quarter average of the corpus (defined as the value of all of the Foundation's assets less any funds held by the Foundation where the donor has directed a different spending provision). Such calculation includes the endowment funds. Any shortfalls of earnings may be made from excess earnings in prior years.

10. Related-Party Transactions

Annual Financial Support

The Foundation entered into an agreement to provide annual financial support to the Hospital (Note 2). The Foundation provided annual financial support of \$31,942 in 2023 and \$33,204 in 2022. Amounts owed to the Hospital under this agreement were \$4,284 at June 30, 2023 and \$2,333 at June 30, 2022.

Operating Expenses

Certain expenditures, primarily operating expenses, are paid by the Hospital and subsequently reimbursed by the Foundation. Accounts payable relating to these transactions were \$1,143 at June 30, 2023 and \$984 at June 30, 2022.

Contributed Services

The Foundation entered into a lease agreement with the Hospital in 2019. Under the agreement, the Hospital agreed to provide office space to the Foundation beginning December 1, 2019. The lease renews annually at the discretion of the Hospital and the Foundation through December 31, 2029.

The Hospital contributed \$484 and \$474 of office space to the Foundation in 2023 and 2022, respectively. Expenses related to these contributed services are included in general and administrative expenses in the statements of activities and changes in net assets. The contributed services are valued using the agreement between the Hospital and the third-party company. The contributed services did not have any donor restrictions.

Conditional Promise to Give

The Board has approved a conditional promise to give to the Hospital, in an amount up to \$30,000 to support existing and future research initiatives. The funding will be provided as the Hospital incurs the expenses and submits requests for funding to the Foundation. To the extent they are available, donor restricted funds will be used to satisfy this promise to give. Any remaining amounts will be funded using net assets without donor restrictions. The funding will be available over the five year period ending in January 2025. The Foundation transferred \$1,714 and \$6,131 to the Hospital under this agreement for the year ended June 30, 2023 and 2022. The Foundation has transferred a total of \$16,814 towards the \$30,000 goal at June 30,2023.

The Board has approved a conditional promise to give to the Hospital, in an amount up to \$31,150 to support capital expenditures for the Heart Institute at UPMC Children's Hospital. The funding will be provided as the Hospital incurs the expenses and submits requests for funding to the Foundation on an annual basis starting in July 2023. To the extent they are available, donor restricted funds will be used to satisfy this promise to give. Any remaining amounts will be funded using net assets without donor restrictions. The estimated completion of the project and related funding is December 31, 2025. No transfers have been made to the Hospital under this agreement for the year ended June 30, 2023.

11. Functional Expenses

The Foundation's primary purpose is to support the fundraising and development efforts of the New CHP. Expenses by functional classification consist of the following for the years ended June 30, 2023 and 2022:

| | 2023 | | | | | | | |
|---|------|--------------------|----|-----------|----|---------------------|-------|------------|
| | P | rogram Fundraising | | draising | | eral and nistrative | Total | |
| Salaries and wages Employee benefits and payroll | \$ | - | \$ | 3,084 | \$ | 1,500 | \$ | 4,584 |
| taxes Contracted services and | | - | | 723 | | 241 | | 964 |
| professional fees | | - | | 2,029 | | 200 | | 2,229 |
| Office supplies and expenses Event expenses | | - | | 72 413 | | 261 - | | 333 413 |
| Other expenses Contributions to UPMC | | - | | 449 | | 825 | | 1,274 |
| Children's Hospital of Pittsburgh, annual financial support and petition requests | | 31,942 | | | | | | 31,942 |
| Total | \$ | 31,942 | \$ | 6,770 | \$ | 3,027 | \$ | 41,739 |

| | 2022 | | | | | | | |
|---|------|-------------|------------------|---------------------------|----|------------------------|-------|------------------------------|
| | P | rogram | gram Fundraising | | | eral and nistrative | Total | |
| Salaries and wages Employee benefits and payroll | \$ | - | \$ | 2,647 | \$ | 1,331 | \$ | 3,978 |
| taxes | | - | | 617 | | 257 | | 874 |
| Contracted services and professional fees Office supplies and expenses Event expenses Other expenses Contributions to UPMC Children's Hospital of | | - - - | | 1,574 87 373 348 | | 208 227 1,970 | | 1,782 314 373 2,318 |
| Pittsburgh, annual financial support and petition requests | | 33,204 | | | | - | | 33,204 |
| Total | \$ | 33,204 | \$ | 5,646 | \$ | 3,993 | \$ | 42,843 |